Sanofi Acquires Hemophilia Treatment Developer Bioverativ for $11.6 Billion
A huge deal is underway as Sanofi looks to acquire Bioverativ for $11.6 billion with hope to enhance and strength their rare disease presence, reports Genetic Engineering & Biotechnology News.…